AbbVie Inc. Q2 2026 Earnings Call Summary

Strategic Performance and Market Dynamics

Our analysts conscionable identified a banal with the imaginable to beryllium the adjacent Nvidia. Tell america however you put and we'll amusement you wherefore it's our #1 pick. Tap here.

• Performance bushed was driven by double-digit maturation successful SKYRIZI, RINVOQ, and the neuroscience portfolio, each exceeding 20% growth.

• Management attributes SKYRIZI's psoriasis enactment to a chiseled illustration of durable tegument clearance and superior head-to-head efficacy versus 5 antithetic mechanisms.

• The acquisition of Apogee Therapeutics is simply a strategical determination to bolster the immunology pipeline with long-acting biologics for the 2030s and beyond.

• Neuroscience outperformance is credited to marketplace stock gains for Vraylar and double-digit maturation crossed the migraine portfolio (Botox, Ubrelvi, Qlipta).

• Oncology results bespeak a modulation play wherever maturation from newer assets similar Elahere and Epkinly is partially offsetting IMBRUVICA's diminution owed to IRA pricing and competition.

• Aesthetics headwinds successful dermal fillers are being addressed done continued concern successful marketplace penetration and the motorboat of the short-acting toxin, BoE.

Strategic Outlook and Guidance Assumptions

• Full-year gross guidance was raised by 300 million, reflecting 600 cardinal successful full raises since the commencement of the twelvemonth based connected commercialized momentum.

• Management anticipates combined highest income for RINVOQ successful vitiligo and alopecia areata to attack $2 billion, importantly higher than anterior expectations.

• The Parkinson's portfolio, including the anticipated motorboat of tevapadone, is expected to execute corporate highest income exceeding $5 billion.

• Guidance assumes the Apogee transaction volition adjacent successful Q3, contributing $0.14 of anticipated dilution portion underlying concern show improves by $0.10.

• Long-term strategy for IBD involves moving toward co-formulated combinations of SKYRIZI with caller antibodies to acceptable caller efficacy bars.

Risk Factors and Structural Dynamics

• HUMIRA income declined 36.1% operationally, a inclination absorption describes arsenic being successful enactment with expectations regarding biosimilar competition.

• The institution is managing a nett leverage ratio people of 2 times wrong 2 to 3 years pursuing the adjacent of the Apogee acquisition.

• IMBRUVICA faces ongoing unit from Medicare Inflation Reduction Act (IRA) pricing impacts and competitory stock loss.

• SKYRIZI regulatory information extortion is noted to past until 2031, with creation of substance patents extending to 2033 and beyond.

Q&A Highlights

Impact of caller oral contention connected SKYRIZI psoriasis stock